Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18983725 | 0.84 | ESR1 (0.46) | ESR1ESR2RORCPPARATSHR | |
| SCHEMBL11424007 | 0.84 | KCNH2 (0.43) | ESR1ESR2RORCMEN1KMT2A | |
| SCHEMBL19980692 | 0.82 | RORC (0.43) | CA2ESR1ESR2RORCMEN1 | |
| SCHEMBL3942362 | 0.81 | TAAR1 (0.52) | ESR1ESR2RORCTDP1KMT2A | |
| SCHEMBL8763390 | 0.79 | ESR1 (0.44) | ESR1ESR2RORCTDP1KMT2A | |
| Hydrochloric Acid SCHEMBL3943536 | 0.79 | TAAR1 (0.50) | ESR1ESR2TDP1KMT2AKDM4E | |
| SCHEMBL6563317 | 0.78 | KIF11 (0.41) | ESR1ESR2RORCTDP1MEN1 | |
| SCHEMBL12044712 | 0.78 | CYP2A6 (0.50) | ESR1ESR2RORCMEN1KMT2A | |
| SCHEMBL1332761 | 0.78 | CA2 (0.48) | CA2ESR1ESR2PPARATDP1 | |
| SCHEMBL6434322 | 0.77 | CA2 (0.52) | CA2ESR1ESR2PPARATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| CN-110325533-A | INHIBITORS OF THE MENIN-MLL INTERACTION | 生命医药有限责任公司 | 2019-10-11 | — | — | CN | disclosed |
| EP-3512850-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CA2 4247/4885ESR1 1404/4885ESR2 2145/4885 |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CA2 4247/4885ESR1 1404/4885ESR2 2145/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CA2 4247/4885ESR1 1404/4885ESR2 2145/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CA2 4247/4885ESR1 1404/4885ESR2 2145/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CA2 4247/4885ESR1 1404/4885ESR2 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.